DALLAS, TX -- June 4, 2025 -- Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate’s latest update shifts the near-term CTx-1301 setup from a PDUFA driven approval event to a CMC-driven resubmission process, while leaving the core product thesis intact based on the information disclosed. The FDA issued a Complete Response Letter for the CTx-1301 NDA focused on specific CMC information requests, with no current clinical safety or efficacy concerns identified. In our view, the key read-through is timing rather than product viability, as the path forward now depends on completing the requested CMC work, resubmitting to FDA, and moving through the next review cycle. Importantly, Cingulate disclosed nearly $30M of cash on hand, which management believes is sufficient to address the FDA’s requests, execute the resubmission process, and continue pre-commercial activities into 2027.
NDA Submission and FDA Approval Pathway: CTx-1301 remains under review through the 505(b)(2) pathway as a once-daily, multi-core dexmethylphenidate tablet using Cingulate’s Precision Timed Release platform. The product’s differentiation is its PTR-enabled tri-modal release design: three timed releases in a single tablet, designed to provide morning onset and later day coverage without the adherence, wear-off, and diversion issues associated with separate afternoon boosters. That positions CTx-1301 as a delivery-driven solution to persistent category gaps around duration, rebound/crash, and booster use, rather than simply another stimulant. Based on the disclosed CRL language, the next regulatory step is centered on CMC response execution, manufacturing documentation, and FDA review timing rather than a disclosed change to the clinical package. Cingulate’s most recent launch framework contemplated commercial launch in 1H27, though timing is now tied to the CMC resubmission and subsequent FDA review. Due to this process being telegraphed by management we are optimistic that the necessary steps are being taken in short order. We currently expect revenue in 2H27.
Clinical Context: The clinical rationale remains supported by the adult and pediatric data package, including Cingulate’s AMCP 2026 pediatric Phase 3 presentation. In that fixed-dose study, CTx-1301 demonstrated statistically significant, dose-dependent improvement in ADHD-RS-5 scores versus placebo, including a -14.16 LS mean difference at the 37.5 mg dose with p<0.001 and an effect size of 1.185. The safety profile remained consistent with the known stimulant class, with no serious treatment-emergent adverse events reported. These data reinforce the intended profile of rapid onset, sustained active-day coverage, and reduced reliance on booster dosing. Cingulate’s materials position CTx-1301 against a market where many leading ADHD therapies address parts of the need, but do not appear to combine the same release profile, active-day durability, crash/rebound reduction, and booster avoidance in one once-daily tablet.
Investment View: The case now centers on turning the CMC-related delay into a clear resubmission path while preserving launch readiness for a differentiated tri-modal ADHD product. Cingulate frames the U.S. stimulant market at over 100M annual prescriptions and approximately $10B, with 1% stimulant market share representing a $250–$300M revenue opportunity. 1Q26 spending had already shifted toward approval-contingent launch work, with R&D of $2.2M, G&A of $5.7M, and a net loss of $9.3M, while nearly $30M of cash supports the CRL response and pre-commercial work into 2027. Longer term, approval would also help validate PTR as a broader delivery platform, though the near-term focus remains CMC completion, resubmission timing, and launch readiness.
Valuation: We use a Discounted Cash Flow Model when valuing CING. Our model returns a valuation range of $19.72 to $32.02 with a mid-point of $24.85.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
SOURCE: Stonegate, Inc.
